Hua Medicine (Shanghai) Ltd. (HKG:2552)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 2.55B -26.2% |
| Revenue (ttm) | 755.49M +76.6% |
| Net Income | -124.44M |
| EPS | -0.13 |
| Shares Out | 996.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,419,500 |
| Open | 2.500 |
| Previous Close | 2.560 |
| Day's Range | 2.500 - 2.620 |
| 52-Week Range | 1.970 - 4.950 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About Hua Medicine (Shanghai)
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) i... [Read more]
Full Company ProfileNews
Hua Medicine (Shanghai) Earnings Call Transcript: H1 2026
Sales and revenue surged in the first half of 2026, with dorzagliatin showing strong growth and efficacy across patient segments. Profitability improved sharply, and the company is on track to reach break-even by year-end, supported by stable pricing, patent extensions, and robust R&D pipeline.
Hua Medicine (Shanghai) Earnings release: H1 2026
Hua Medicine (Shanghai) released its H1 2026 earnings on August 20, 2026, summarizing the period's financial results.
Hua Medicine (Shanghai) Slides: H1 2026
Hua Medicine (Shanghai) has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 20, 2026.
Hua Medicine (Shanghai) Earnings Call Transcript: H2 2025
Revenue grew 93% year-over-year to nearly RMB 500 million, driven by a 91% increase in sales volume and expanded market access. Gross profit margin improved, selling expenses dropped, and profitability was achieved in commercialization. Patent and NRDL price extensions support long-term growth.
Hua Medicine (Shanghai) Earnings release: H2 2025
Hua Medicine (Shanghai) released its H2 2025 earnings on March 26, 2026, summarizing the period's financial results.
Hua Medicine (Shanghai) Slides: H2 2025
Hua Medicine (Shanghai) has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 26, 2026.
Hua Medicine (Shanghai) Annual report: H2 2025
Hua Medicine (Shanghai) has published its H2 2025 annual report on March 26, 2026.
Hua Medicine (Shanghai) Earnings Call Transcript: H1 2025
Revenue more than doubled year-over-year in H1 2025, driven by Dorzagliatin's commercialization and operational efficiency, with gross margin rising to 54%. Confident in reaching RMB 1 billion sales by 2027, supported by global expansion and new product launches.
Hua Medicine (Shanghai) Quarterly report: H1 2025
Hua Medicine (Shanghai) has published its H1 2025 quarterly earnings report on August 28, 2025.
Hua Medicine (Shanghai) Earnings release: H1 2025
Hua Medicine (Shanghai) released its H1 2025 earnings on August 28, 2025, summarizing the period's financial results.
Hua Medicine (Shanghai) Slides: H1 2025
Hua Medicine (Shanghai) has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 28, 2025.